Literature DB >> 11168685

Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter.

H Hashimoto1, Y Sue, Y Saga, M Tokumitsu, S Yachiku.   

Abstract

BACKGROUND: The significance of p53 overexpression for the prognosis of transitional cell carcinoma (TCC) of the renal pelvis and ureter remains controversial. Simultaneous evaluation of p53 and MDM2 may enable better prediction of tumor proliferation and patient prognosis than that obtained with evaluation of p53 alone.
METHODS: Immunohistochemical detection of p53 protein, MDM2 protein and Ki-67 antigen as proliferation markers was performed for tissue samples obtained from 74 patients with TCC of the renal pelvis and ureter. The correlations of p53/MDM2 overexpression with conventional pathological features, Ki-67 labelling index (LI) and patient survival were studied.
RESULTS: Overexpression of p53 was related to progression of each of the pathological features examined (grade, stage, type of infiltration, vascular invasion and lymphatic invasion) and Ki-67 LI was significantly higher with high p53 expression than with low p53 expression. However, overexpression of MDM2 was related to neither disease progression nor Ki-67 LI. Survival analyses were performed for 66 patients. Univariate analysis showed p53 to be a useful prognostic indicator, but in a multivariate analysis only type of infiltration and Ki-67 LI were independent survival markers, while p53 was not. Overexpression of MDM2 was unrelated to patient survival, and the combination of p53 and MDM2 for survival indication was found not to be useful.
CONCLUSIONS: Overexpression of p53 is related to disease progression, increased tumor proliferation and patient survival for TCC of the renal pelvis and ureter, but the independent prognostic value of p53 did not reach statistical significance. Combined analysis of MDM2 with p53 cannot be recommended for examination of the malignant potential of TCC of the renal pelvis and ureter.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11168685     DOI: 10.1046/j.1442-2042.2000.00230.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  5 in total

Review 1.  Expression of p53 in upper urinary tract urothelial carcinoma.

Authors:  Stephen Mitchell; Erik Mayer; Anup Patel
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

Review 2.  Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma.

Authors:  Qiang Li; Aditya Bagrodia; Eugene K Cha; Jonathan A Coleman
Journal:  Curr Urol Rep       Date:  2016-02       Impact factor: 3.092

3.  Predictive value of clinicopathological markers for the metachronous bladder cancer and prognosis of upper tract urothelial carcinoma.

Authors:  Chenchen Feng; Lujia Wang; Guanxiong Ding; Qiang Ding; Zhongwen Zhou; Haowen Jiang; Zhong Wu
Journal:  Sci Rep       Date:  2014-02-06       Impact factor: 4.379

4.  MDM2 Contributes to High Glucose-Induced Glomerular Mesangial Cell Proliferation and Extracellular Matrix Accumulation via Notch1.

Authors:  Chun-Tao Lei; Hui Tang; Chen Ye; Chao-Qun You; Jiao Zhang; Chun-Yun Zhang; Wei Xiong; Hua Su; Chun Zhang
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

5.  Evaluation of P53 and CK20 Immunohistochemical Markers in Comparison with Morphologic Findings in Low- and High-grade Urothelial Carcinomas.

Authors:  Mahsa Ahadi; Afshin Moradi; Banafshe Bayat; Hanieh Zham; Seyed Jalil Hosseini; Sara Zahedifar; Afsoon Taghavi
Journal:  Iran J Pathol       Date:  2021-05-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.